FREDERIC DEZOTEUX

Dr. FREDERIC DEZOTEUX

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
ALAmélie Leurs
Amélie Leurs
CCCécile Chenivesse
Cécile Chenivesse
BLBenjamin Lopez
Benjamin Lopez
JGJean-Baptiste Gibier
Jean-Baptiste Gibier
GCGuillaume Clément
Guillaume Clément
GLGuillaume Lefèvre
Guillaume Lefèvre

16 February 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
ICIngrid Costedoat
Ingrid Costedoat
MWMartin Wallaert
Martin Wallaert
AGAurelie Gaultier
Aurelie Gaultier
RVRobin Vasseur
Robin Vasseur
CVClelia Vanhaecke
Clelia Vanhaecke
F(France French Atopic Dermatitis Network From The Groupe de Recherche Sur L'Eczema Atopique (Great)
France French Atopic Dermatitis Network From The Groupe de Recherche Sur L'Eczema Atopique (Great)

5 January 2025 in Allergy
Verified
Journal Article
Closed access
GLGuillaume Lefèvre
Guillaume Lefèvre
SBSéverine Bleuse
Séverine Bleuse
MPMathieu Puyade
Mathieu Puyade
GMGuillaume Moulis
Guillaume Moulis
ANAntoine Néel
Antoine Néel
MGMatthieu Groh
Matthieu Groh

28 August 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
CMC. Marcombes
C. Marcombes
SIS. Ingen‐Housz‐Oro
S. Ingen‐Housz‐Oro
FDFREDERIC DEZOTEUX
FREDERIC DEZOTEUX
DSD. Staumont‐Sallé
D. Staumont‐Sallé
BMB. Milpied
B. Milpied
VDV. Descamps
V. Descamps

1 August 2019 in European Journal Of Dermatology
Verified
Journal Article
Closed access
PDF file
FDFREDERIC DEZOTEUX
FREDERIC DEZOTEUX
BABellissen Astrid
Bellissen Astrid
MCMarie Chuffard
Marie Chuffard
EDElodie Drumez
Elodie Drumez
SASelma Azib
Selma Azib
DSDelphine Staumont-Sallé
Delphine Staumont-Sallé
Atopic dermatitis (AD) in adults over 45 years of age (AD≥45) has been poorly studied. To determine whether the AD phenotype varies according to the pattern of AD onset in AD≥45 patients and whether response to cyclosporine A (CsA) is influenced by age. This monocentric retrospective study was performed in a French university department of dermatology. We included 409 AD<45 patients (111 treated with CsA) and 124 AD≥45 patients (26 treated with CsA). Among AD≥45 patients, 20% were categorised into Subgroup 1 (persistence of AD since childhood), 52% into Subgroup 2 (recurrence of AD with a history of classic childhood AD), and 28% into Subgroup 3 (adult-onset AD). Gender, associated atopic comorbidities, a family history of atopy, and AD severity were similar regarding the different patterns of AD onset in AD≥45 patients. Skin lesions predominated on the face and neck in AD≥45 patients with AD since childhood (30% in Subgroups 1 and 2) compared to those with adult-onset AD (14% in Subgroup 3). The efficacy of CsA was similar between groups AD≥45 and AD<45, but 28% of AD≥45 patients versus 20% of AD<45 patients had increased serum creatinine levels under CsA. No significant association seems to exist between the onset of AD and demographic or clinical characteristics in AD≥45 patients (except that head and neck involvement is rarer in adult-onset AD). Patient age does not influence response to CsA, but this drug appears to be less well tolerated in older patients.

26 July 2024 in Allergy
Verified
Journal Article
Open access
GPGuillaume Pierrard
Guillaume Pierrard
CBClaire Bernier
Claire Bernier
ADAurélie Du‐Thanh
Aurélie Du‐Thanh
CBCorina Bara
Corina Bara
ASAngèle Soria
Angèle Soria
FDFREDERIC DEZOTEUX
FREDERIC DEZOTEUX
Background: Limited information is available on the use of omalizumab (OMA) updosing since its introduction as a second‐line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes in dose and/or injection intervals), to identify the predictive factors associated with updosing, and to improve CSU management.Methods: We conducted a prospective, multicentric, real‐life observational study, including patients diagnosed with CSU and starting OMA. The data were collected at 0, 3, 6, and 9 months. The primary endpoint was the frequency of OMA updosing at 3 months. The secondary endpoints included an analysis of updosed patients' profile, and an assessment of OMA efficacy and safety.Results: We included 153 patients. Twenty percent of patients were updosed at 3 months, and 27% in total during the 9‐month follow‐up. Practitioners mainly chose to increase the frequency of injections (66%). At baseline, the updosed patients were more likely to have more severe CSU (UCT < 4, p < 0.030), a lower lymphocyte count (<2000/mm3, p = 0.037), and low IgE levels (<70 UI/mL, p = 0.024). The side effects of OMA were not more frequent after updosing.Conclusion: One in five patient underwent updosing within just 3 months. OMA updosing is frequent in particular in cases of severe disease and low IgE blood levels.